TAVR is the only chance this company have, the patch market although becoming profitable will not excite the market.
Only a TAVR deal will cut it for us with one of the majors.
Not only the project will be funded to commercialism, the company will get IP protection, going alone with it not only too expensive for Admedus to partake, it will open the gates to litigation, just look what apple did to Samsung.
this will be where surgeons will prefer our TAVR:
https://www.dicardiology.com/content/tavr-outperforms-surgery-younger-low-risk-aortic-stenosis-patients
with our tissue lasting the longest, younger patients would want a product that last so they don't have to undergo surgery in 8 years or less, in case the retrieval of the failing valve fails.
good luck to us all, we really deserve a break.
TAVR is the only chance this company have, the patch market...
-
- There are more pages in this discussion • 176 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |